Dhaval Patel

Dhaval Patel

Company: UCB

Job title: Executive Vice President & Chief Scientific Officer


Therapeutic Potential in Targeting the FcRn Receptor: Clinical Overview & Future Opportunities 9:00 am

The effectiveness of FcRn inhibitors in autoimmune diseases, including myasthenia gravis and immune thrombocytopenia, provides further evidence that IgG is a primary driver in these autoantibody-mediated diseases An update of UCB’s clinical activities and future directions in brining fist in class therapeutics to autoimmune patientsRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.